- $476.89m
- $512.42m
- $71.61m
Avita Medical Inc Expected To Post A Loss Of 29 Cents A Share: Earnings Preview
Avita Medical Inc Expected To Post A Loss Of 29 Cents A Share: Earnings Preview
Brief: AVITA Medical Chief Financial Officer Announces Departure
U.S. RESEARCH ROUNDUP-Inter Parfums, Marsh & McLennan, Treehouse Foods
Brief: AVITA Medical Submits FDA Pma Application To Expand Indication To Vitiligo
Brief: Avita Medical Inc Says Submits FDA PMA Application To Expand Indication To Vitiligo
Brief: AVITA Medical Submits FDA PMA Supplement To Further Expand Indication To Soft Tissue Repair
Brief: AVITA Medical Reports Third Quarter 2022 Financial Results
Primary Endpoints In Updated Analysis Of Pivotal Trial Of Recell System For Soft Tissue Repair
Brief: Avita Medical Appoints James Corbett As CEO
Brief: Avita Medical Appoints James Corbett As Chief Executive Officer
Avita Medical rises on skin disorder treatment trial success
Brief: Avita Medical Achieves Positive Topline Pivotal Trial Results For Treatment Of Stable Vitiligo Using Recell System
Brief: Avita Medical Reports Second Quarter 2022 Financial Results
Brief: Avita Medical Announces Topline Results From Pivotal Trial In Patients With Soft-Tissue Injuries Using The Recell System
U.S. RESEARCH ROUNDUP-First Solar, Henry Schein, Petiq
Brief: AVITA Medical Reports First Quarter 2022 Financial Results
Brief: Avita Medical, Inc. Announces Resignation Of Louis Drapeau From Board Of Directors
Australia Stock Exchange release from AVITA MED CDI : RECELL Vitiligo Protocol Presentation at Vitiligo Symposium